PubMed: Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing

PubMed: Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing

J Clin Sleep Med. 2024 Jan 4. doi: 10.5664/jcsm.10998. Online ahead of print.

ABSTRACT

STUDY OBJECTIVES: Low dose cannabidiol (CBD) has become readily available in numerous countries; however, little consensus exists on its efficacy as a sleep aid. This trial explored the efficacy of 150 mg of CBD (n=15) compared to placebo (n=15) as a sleep aid in primary insomnia. CBD supplementation was hypothesized to decrease insomnia symptoms and improve aspects of psychological health, relative to placebo.

METHODS: Using a randomized, placebo-controlled parallel design featuring a single-blind placebo run-in week followed by a two-week double-blind randomized dosing phase, participants consumed the assigned treatment sublingually 60 minutes before bed nightly. Wrist-actigraphy and sleep diaries measured daily sleep. Sleep quality, sleep effort and well-being were measured weekly over four in-lab visits. Insomnia severity and trait anxiety were measured at screening and study conclusion.

RESULTS: Insomnia severity, subjective sleep onset latency, sleep efficiency and wake after sleep onset did not differ between treatments throughout the trial (all p>0.05). Compared to placebo, the CBD group reported greater well-being scores throughout the trial (trial end mean difference=2.60, SE 1.20), transient elevated behavior following wakefulness scores after 1 week of treatment (mean difference=3.93, SE 1.53) and had superior objective sleep efficiency after 2 weeks of treatment (mean difference=6.85, SE 2.95) (all p<0.05). No other significant treatment effects were observed.

CONCLUSIONS: Nightly supplementation of 150 mg CBD was similar to placebo regarding most sleep outcomes whilst sustaining greater well-being, suggesting more prominent psychological effects. Additional controlled trials examining varying treatment periods and doses are crucial.

CLINICAL TRIAL REGISTRATION: Registry: Australian New Zealand Clinical Trials Registry; Title: Cannabidiol (CBD) treatment for insomnia; Identifier: ACTRN12620000070932; URL: https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12620000070932.

PMID:38174873 | DOI:10.5664/jcsm.10998

https://pubmed.ncbi.nlm.nih.gov/38174873/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Ds1JEbG0OWaBdqM3tTUGjkFhFGaOtMecPdpuvzbuubWi6d9Fn&fc=20231022105433&ff=20240104132148&v=2.18.0 January 4, 2024 11:00 am